Unknown

Dataset Information

0

Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.


ABSTRACT: This open-label drug-drug interaction study assessed whether blockade by dupilumab of interleukin (IL)-4 and IL-13 signaling affects the pharmacokinetics of drugs metabolized by cytochrome P450 (CYP450) enzymes. The pharmacokinetics of five CYP450 substrates given orally (midazolam, omeprazole, S-warfarin, caffeine, and metoprolol, metabolized by CYP3A, CYP2C19, CYP2C9, CYP1A2, and CYP2D6, respectively) were evaluated before and 28 days after initiation of dupilumab treatment (subcutaneous 300?mg weekly) in 14 patients with moderate-to-severe atopic dermatitis. Dupilumab had no clinically relevant effects on the pharmacokinetics of CYP450 substrates, provided substantial clinical benefit, and was generally well tolerated. Only one serious adverse event was reported, an episode of systemic inflammatory response syndrome that resolved after treatment was discontinued. In summary, blockade of IL-4/IL-13 signaling in patients with type 2 inflammation does not appear to significantly affect CYP450 enzyme activities; the use of dupilumab in atopic dermatitis patients is unlikely to influence the pharmacokinetics of CYP450 substrates.

SUBMITTER: Davis JD 

PROVIDER: S-EPMC6282936 | biostudies-literature | 2018 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Evaluation of Potential Disease-Mediated Drug-Drug Interaction in Patients With Moderate-to-Severe Atopic Dermatitis Receiving Dupilumab.

Davis John D JD   Bansal Ashish A   Hassman David D   Akinlade Bolanle B   Li Meng M   Li Zhaoyang Z   Swanson Brian B   Hamilton Jennifer D JD   DiCioccio A Thomas AT  

Clinical pharmacology and therapeutics 20180402 6


This open-label drug-drug interaction study assessed whether blockade by dupilumab of interleukin (IL)-4 and IL-13 signaling affects the pharmacokinetics of drugs metabolized by cytochrome P450 (CYP450) enzymes. The pharmacokinetics of five CYP450 substrates given orally (midazolam, omeprazole, S-warfarin, caffeine, and metoprolol, metabolized by CYP3A, CYP2C19, CYP2C9, CYP1A2, and CYP2D6, respectively) were evaluated before and 28 days after initiation of dupilumab treatment (subcutaneous 300 m  ...[more]

Similar Datasets

| S-EPMC9782472 | biostudies-literature
| S-EPMC8776905 | biostudies-literature
| S-EPMC9542087 | biostudies-literature
| S-EPMC9306756 | biostudies-literature
| S-EPMC9842774 | biostudies-literature
| S-EPMC6692787 | biostudies-literature
| S-EPMC9366658 | biostudies-literature
| S-EPMC8340015 | biostudies-literature
| S-EPMC8081439 | biostudies-literature
| S-EPMC7859021 | biostudies-literature